Contraceptives, Oral

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

3 weeks ago talkbio0Tagged alpha 1-antitrypsin, Artificial Intelligence, Automation, Contraceptives, Oral, eli lilly, Obesity, orforglipron, pharmaceutical manufacturing, Supply Chain Resilience, Surgical construction, Texas Facility

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation

Novo Nordisk Awaits FDA Decision on Oral Wegovy Pill for Obesity

4 weeks ago talkbio0Tagged Approved, Cardiovascular Risk, Contraceptives, Oral, Glucagon-Like Peptide 1, Nordisk, Obesity, oral semaglutide, United States Food and Drug Administration, Wegovy, Weight Loss

Novo Nordisk; Wegovy; oral semaglutide; FDA approval; obesity treatment; GLP-1 pill; weight loss; cardiovascular risk

Lilly to Seek Global Approval for GLP-1 Pill After Obesity and Diabetes Trial Success

2 months ago talkbio0Tagged Approved, Clinical Trials, Contraceptives, Oral, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Glucagon-Like Peptide 1, Obesity, orforglipron, United States Food and Drug Administration, Weight Loss

Eli Lilly; GLP-1 pill; orforglipron; obesity; type 2 diabetes; FDA approval; weight loss; clinical trial

Viking Therapeutics Shares Crash After Obesity Pill VK2735 Delivers 12% Weight Loss, But Side Effects and Discontinuations Raise Concerns

2 months ago talkbio0Tagged Adverse event, aspects of adverse effects, Clinical Trials, Contraceptives, Oral, drug efficacy, gastrointestinal, Obesity, Stock Crash, Viking, VK2735, Weight Loss

Viking Therapeutics; VK2735; obesity pill; weight loss; clinical trial; stock crash; side effects; adverse events; gastrointestinal; drug efficacy

Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly’s Pill Shows Modest Results

2 months ago talkbio0Tagged competition, Contraceptives, Oral, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Obesity, oral semaglutide, orforglipron, Wegovy, Weight-Loss Agents, Zepbound

Novo Nordisk; Eli Lilly; obesity pill; oral semaglutide; orforglipron; weight loss drugs; Wegovy; Zepbound; GLP-1; market competition

Mayne Pharma Faces FDA Action Over ‘Misleading’ Drug Safety Claims Ahead of $430M Buyout

5 months ago talkbio0Tagged Claims, Contraceptives, Oral, Cosette Pharmaceuticals, drug safety, Mayne, Nextstellis, Pharma, United States Food and Drug Administration

Mayne Pharma; FDA; misleading claims; Nextstellis; birth control pill; drug safety; buyout; Cosette Pharmaceuticals

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

6 months ago talkbio0Tagged Accelerated, Agencies, Artificial Intelligence, Califf, Contraceptives, Oral, Infrequent, RIFs, United States Food and Drug Administration, Unspecified Abortion

United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies

Trump pledges his support for a change to the IRA long sought by drugmakers

6 months ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout

7 months ago talkbio0Tagged Acelyrin, Capital Partners, Concentra Biosciences, Contraceptives, Oral, Pliant, Poisons, Tang

Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense

Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results

1 year ago talkbio0Tagged aspects of adverse effects, concerns, Contraceptives, Oral, CT-996, Effectiveness, Gastrointestinal Issues, Nausea, Obesity, Roche (company), Safety, Vomiting

Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues